首页 | 本学科首页   官方微博 | 高级检索  
     


Synthesis,Biological Evaluation of 1,1‐Diarylethylenes as a Novel Class of Antimitotic Agents
Authors:Abdallah Hamze Dr.  Anne Giraud Dr.  Samir Messaoudi Dr.  Olivier Provot Dr.  Jean‐François Peyrat Prof.  Jérôme Bignon Dr.  Jian‐Miao Liu Dr.  Joanna Wdzieczak‐Bakala Dr.  Sylviane Thoret  Joëlle Dubois Dr.  Jean‐Daniel Brion Prof.  Mouad Alami Dr.
Affiliation:1. Université Paris‐Sud, CNRS, BioCIS‐UMR 8076, Laboratoire de Chimie Thérapeutique, Faculté de Pharmacie, 5 rue J.‐B. Clément, Chatenay‐Malabry, 92296 (France), Fax: (+33)?146‐83‐58‐28;2. Institut de Chimie des Substances Naturelles, UPR 2301, CNRS, Avenue de la Terrasse, Gif sur Yvette, 91198 (France)
Abstract:The cytotoxic activities of 23 new isocombretastatin A derivatives with modifications on the B‐ring were investigated. Several compounds exhibited excellent antiproliferative activity at nanomolar concentrations against a panel of human cancer cell lines. Compounds isoFCA‐4 ( 2 e ), isoCA‐4 ( 2 k ) and isoNH2CA‐4 ( 2 s ) were the most cytotoxic, and strongly inhibited tubulin polymerization with IC50 values of 4, 2 and 1.5 μM , respectively. These derivatives were found to be 10‐fold more active than phenstatin and colchicine with respect to growth inhibition but displayed similar activities as tubulin polymerization inhibitors. In addition, cell cycle arrest in the G2/M phase and subsequent apoptosis was observed in three cancer cell lines when treated with these compounds. The disruptive effect of 2 e , 2 k and 2 s on the vessel‐like structures formed by human umbilical vein endothelial cells (HUVEC) suggest that these compounds may act as vascular disrupting agents. Both compounds 2 k and 2 s have the potential for further prodrug modification and development as vascular disrupting agents for treatment of solid tumors.
Keywords:antitumor agents  combretastatin A‐4  cytotoxicity  inhibitors  tubulin  vascular disrupting agents
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号